Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death

Abstract Aims The E3-ligase CBL-B (Casitas B-cell lymphoma-B) is an important negative regulator of T cell activation that is also expressed in macrophages. T cells and macrophages mediate atherosclerosis, but their regulation in this disease remains largely unknown; thus, we studied the function of CBL-B in atherogenesis. Methods and results The expression of CBL-B in human atherosclerotic plaques was lower in advanced lesions compared with initial lesions and correlated inversely with necrotic core area. Twenty weeks old Cblb−/−Apoe−/− mice showed a significant increase in plaque area in the aortic arch, where initial plaques were present. In the aortic root, a site containing advanced plaques, lesion area rose by 40%, accompanied by a dramatic change in plaque phenotype. Plaques contained fewer macrophages due to increased apoptosis, larger necrotic cores, and more CD8+ T cells. Cblb−/−Apoe−/− macrophages exhibited enhanced migration and increased cytokine production and lipid uptake. Casitas B-cell lymphoma-B deficiency increased CD8+ T cell numbers, which were protected against apoptosis and regulatory T cell-mediated suppression. IFNγ and granzyme B production was enhanced in Cblb−/−Apoe−/− CD8+ T cells, which provoked macrophage killing. Depletion of CD8+ T cells in Cblb−/−Apoe−/− bone marrow chimeras rescued the phenotype, indicating that CBL-B controls atherosclerosis mainly through its function in CD8+ T cells. Conclusion Casitas B-cell lymphoma-B expression in human plaques decreases during the progression of atherosclerosis. As an important regulator of immune responses in experimental atherosclerosis, CBL-B hampers macrophage recruitment and activation during initial atherosclerosis and limits CD8+ T cell activation and CD8+ T cell-mediated macrophage death in advanced atherosclerosis, thereby preventing the progression towards high-risk plaques.

[1]  A. Pandey,et al.  Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. , 2018, Circulation.

[2]  K. Peter,et al.  Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges , 2017, British journal of pharmacology.

[3]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[4]  A. Gabrielsen,et al.  Gene expression signatures, pathways and networks in carotid atherosclerosis , 2016, Journal of internal medicine.

[5]  G. Hansson,et al.  Adaptive Response of T and B Cells in Atherosclerosis. , 2016, Circulation research.

[6]  L. Boon,et al.  CD8+ T Cells Regulate Monopoiesis and Circulating Ly6C-high Monocyte Levels in Atherosclerosis in Mice. , 2015, Circulation research.

[7]  D. Wolf,et al.  Modulation of Immune Cell Functions by the E3 Ligase Cbl-b , 2015, Front. Oncol..

[8]  A. Viola,et al.  Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells. , 2013, Journal of molecular cell biology.

[9]  F. Pontén,et al.  Profiling of Atherosclerotic Lesions by Gene and Tissue Microarrays Reveals PCSK6 as a Novel Protease in Unstable Carotid Atherosclerosis , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[10]  T. Nikawa,et al.  Cbl-b Is a Critical Regulator of Macrophage Activation Associated With Obesity-Induced Insulin Resistance in Mice , 2013, Diabetes.

[11]  P. Tipping,et al.  Cytotoxic and Proinflammatory CD8+ T Lymphocytes Promote Development of Vulnerable Atherosclerotic Plaques in ApoE-Deficient Mice , 2013, Circulation.

[12]  C. Ballantyne,et al.  Regulation of LFA-1-dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteins. , 2008, Blood.

[13]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[14]  J. Christman,et al.  E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury , 2007, Nature Medicine.

[15]  Josef M. Penninger,et al.  Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells , 2007, The Journal of experimental medicine.

[16]  F. Tacke,et al.  Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Penninger,et al.  Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. , 2004, Immunity.

[18]  C. Elly,et al.  Cbl-b, a RING-type E3 Ubiquitin Ligase, Targets Phosphatidylinositol 3-Kinase for Ubiquitination in T Cells* , 2001, The Journal of Biological Chemistry.

[19]  E. Shevach,et al.  Cbl-b regulates the CD28 dependence of T-cell activation , 2000, Nature.